These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 36326416)
1. The correlation of serum sPD-1 and sPD-L1 levels with clinical, pathological characteristics and lymph node metastasis in nonsmall cell lung cancer patients. Ancın B; Özercan MM; Yılmaz YM; Uysal S; Kumbasar U; Sarıbaş Z; Dikmen E; Doğan R; Demircin M Turk J Med Sci; 2022 Aug; 52(4):1050-1057. PubMed ID: 36326416 [TBL] [Abstract][Full Text] [Related]
2. Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients. Li C; Li C; Zhi C; Liang W; Wang X; Chen X; Lv T; Shen Q; Song Y; Lin D; Liu H J Transl Med; 2019 Oct; 17(1):355. PubMed ID: 31665020 [TBL] [Abstract][Full Text] [Related]
3. Molecular Mechanism of Expression Changes of Immunological Indexes of PD-1/sPD-L1 after Radiotherapy in Nonsmall Cell Lung Cancer. Qu Y; Wang H; Liu H; Sun X; Li J; Yu H Biomed Res Int; 2021; 2021():8811751. PubMed ID: 33987445 [TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of soluble PD-L1 derived from tumor-associated macrophages in non-small-cell lung cancer. Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y Cancer Immunol Immunother; 2023 Nov; 72(11):3755-3764. PubMed ID: 37646826 [TBL] [Abstract][Full Text] [Related]
5. Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer. Okuma Y; Wakui H; Utsumi H; Sagawa Y; Hosomi Y; Kuwano K; Homma S Clin Lung Cancer; 2018 Sep; 19(5):410-417.e1. PubMed ID: 29859759 [TBL] [Abstract][Full Text] [Related]
6. Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibody. Murakami S; Shibaki R; Matsumoto Y; Yoshida T; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Yamamoto N; Ohe Y Thorac Cancer; 2020 Dec; 11(12):3585-3595. PubMed ID: 33108686 [TBL] [Abstract][Full Text] [Related]
7. Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy. Zhao J; Zhang P; Wang J; Xi Q; Zhao X; Ji M; Hu G Medicine (Baltimore); 2017 Feb; 96(7):e6102. PubMed ID: 28207525 [TBL] [Abstract][Full Text] [Related]
8. [Programmed cell death protein 1 and its ligands regulate immune balance in allergic rhinitis]. Wen SL; Li F; Zhao F; Zuo JJ; Deng YQ; Zhang W; Tao ZZ Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 Apr; 55(4):384-390. PubMed ID: 32306637 [No Abstract] [Full Text] [Related]
9. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma. Han X; Gu YK; Li SL; Chen H; Chen MS; Cai QQ; Deng HX; Zuo MX; Huang JH J Cancer Res Clin Oncol; 2019 Feb; 145(2):303-312. PubMed ID: 30267213 [TBL] [Abstract][Full Text] [Related]
10. Soluble PD-L1 shows no association to relapse and overall survival in early stage non-small cell lung cancer (NSCLC). Mildner FO; Sykora MM; Hackl H; Amann A; Zelger B; Sprung S; Buch ML; Nocera F; Moser P; Maier H; Augustin F; Manzl C; Kocher F; Pircher A; Lindenmann J; Mykoliuk I; Raftopoulou S; Kargl J; Wolf D; Sopper S; Gamerith G Lung Cancer; 2024 Oct; 196():107955. PubMed ID: 39306924 [TBL] [Abstract][Full Text] [Related]
11. Decreased serum soluble programmed cell death ligand-1 level as a potential biomarker for missed miscarriage. Li Q; Chen C; Wu J; Poon LC; Wang CC; Li TC; Zhang T; Guo X; Song L; Wang X; Zhang Q; Ye Z; Yang Y; Lu J; Yao J; Ye D; Wang Y Hum Reprod; 2023 Nov; 38(11):2128-2136. PubMed ID: 37671597 [TBL] [Abstract][Full Text] [Related]
12. Plasma sPD-L1 and VEGF levels are associated with the prognosis of NSCLC patients treated with combination immunotherapy. Dong C; Hui K; Gu J; Wang M; Hu C; Jiang X Anticancer Drugs; 2024 Jun; 35(5):418-425. PubMed ID: 38386011 [TBL] [Abstract][Full Text] [Related]
13. The influence of plasma sPD-L1 concentration on the effectiveness of immunotherapy in advanced NSCLC patients. Chmielewska I; Grenda A; Krawczyk P; Frąk M; Kuźnar Kamińska B; Mitura W; Milanowski J Cancer Immunol Immunother; 2023 Dec; 72(12):4169-4177. PubMed ID: 37816808 [TBL] [Abstract][Full Text] [Related]
14. [The content of the soluble forms PD-1 and PD-L1 in blood serum of patients with gastric cancer and their relationship with clinical and morphological characteristics of the disease.]. Gershtein ES; Ognerubov NA; Chang VL; Delektorskaya VV; Korotkova EA; Sokolov NY; Polikarpova SB; Stilidi IS; Kushlinskii NE Klin Lab Diagn; 2020; 65(6):347-352. PubMed ID: 32459892 [TBL] [Abstract][Full Text] [Related]
15. B7-1 and programmed cell death-ligand 1 in primary and lymph node metastasis lesions of non-small cell lung carcinoma. Yamada T; Miki Y; Suzuki M; Kondoh O; Saito-Koyama R; Ono K; Okada Y; Sasano H Cancer Med; 2022 Jan; 11(2):479-491. PubMed ID: 34907653 [TBL] [Abstract][Full Text] [Related]
16. High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer. Okuma Y; Hosomi Y; Nakahara Y; Watanabe K; Sagawa Y; Homma S Lung Cancer; 2017 Feb; 104():1-6. PubMed ID: 28212990 [TBL] [Abstract][Full Text] [Related]
17. [The level of soluble programmed death-1 in peripheral blood of patients with lung cancer and its clinical implications]. Xing YF; Zhang ZL; Shi MH; Ma Y; Chen YJ Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):102-6. PubMed ID: 22455965 [TBL] [Abstract][Full Text] [Related]
18. [Level of soluble programmed death-1 ligand 1 in peripheral blood of patients with advanced epidermal growth factor receptor mutated lung adenocarcinoma and its clinical implications]. Zhang LQ; Chen Y; Pan X; Xing YF; Shi MH; Chen YJ Zhonghua Yi Xue Za Zhi; 2016 Dec; 96(48):3870-3874. PubMed ID: 28057155 [No Abstract] [Full Text] [Related]
19. Study on the Expression Levels and Clinical Significance of PD-1 and PD-L1 in Plasma of NSCLC Patients. He J; Pan Y; Guo Y; Li B; Tang Y J Immunother; 2020 Jun; 43(5):156-164. PubMed ID: 32168233 [TBL] [Abstract][Full Text] [Related]
20. Increase of Soluble Programmed Cell Death Ligand 1 in Patients with Chronic Hepatitis C. Yamagiwa S; Ishikawa T; Waguri N; Sugitani S; Kamimura K; Tsuchiya A; Takamura M; Kawai H; Terai S Int J Med Sci; 2017; 14(5):403-411. PubMed ID: 28539815 [No Abstract] [Full Text] [Related] [Next] [New Search]